Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
The present invention relates to an agent for increasing BMD characterized by use of a cathepsin K inhibitor as a bone resorption inhibitor in combination with a type of PTH as a bone formation stimulator. This agent for increasing BMD is useful for the treatment of osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcemia, osteometastasis of carcinoma, periodontal disease, bone Paget's disease and other bone metabolic diseases. For example, as the cathepsin K inhibitor, there can be mentioned a compound of formula (W) and a salt thereof, etc.
1. A method for increasing bone mineral density, comprising administering to a mammal an effective amount of an agent comprising a cathepsin K inhibitor and a type of PTH,
wherein the cathepsin K inhibitor is a compound of formula (W-1):
wherein R S and R T are each independently a hydrogen atom or a C1-4 alkyl group, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof; and
wherein the type of PTH is human PTH (1-34).
2. The method according to claim 1 , wherein the agent is an agent for treating a bone metabolic disease.
3. The method according to claim 1 , wherein the compound of formula (W-1) is
(1) N-{3-[(2Z)-2-(3-methyl-1,3-thiazolidin-2-ylidene)hydrazine]-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl }cycloheptanecarboxamide,
(2) N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide,
(3) N-((1S)-3-{(2Z)-2-[(4S)-3-ethyl-4-methyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxalflide,
(4) N-((1R)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptaneCarboxamide,
(5) N-(3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxamide or
(6) (N-((1S)-3-{(2Z)-2-[(4S)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxalmde).
4. The method according to claim 3 , wherein the compound of formula (W-1) is
N-{3-[(2Z)-2-(3-methyl-1,3 -thiazolidin-2-ylidene)hydrazine]-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl}cycloheptanecarboxamide or
N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide.
5. The method according to claim 1 , wherein the compound of formula (W-1) is orally administered and the human PTH (1-34) is parenterally administered.
6. The method according to claim 1 , wherein the agent further comprises one or more selected from a prostaglandin receptor agonist, a prostaglandin receptor antagonist, an ergocalciferol, a cholecalciferol, an alphacalcidol, a falecalcitriol, a calcitriol, a 1α,25-dihydroxycholecarciferol, a dihydrotachysterol, a ST-630, a KDR, a ST-630, an ED-71, a rocaltrol, a calcium formulation, a phyonadione, a menatetrenone, a calcitonin formulation, a strontium formulation, an estrogen receptor modulator, anti-TNF-α antibody, anti-IL-6 antibody, an HMG-CoA reductase inhibitor, a female hormone formulation, an antiinflammatory drug, PTHrP, a bone formation protein formulation, an androgen receptor modulator, a steroidal drug, a caspase-1 inhibitor, a farnesoid X receptor agonist, a progesteron agonist, anti-RANKL antibody, a metalloprotease inhibitor, a protein assimilation steroidal formulation, a calcium sensing receptor antagonist and a glycogen synthase kinase inhibitor.
7. The method according to claim 2 , wherein the bone metabolic disease is osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcemia, osteometastasis of carcinoma, osteosarcoma, periodontal disease and/or bone Paget's disease.